Expert Opinion on Pharmacotherapy

Papers
(The H4-Index of Expert Opinion on Pharmacotherapy is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy37
Comprehensive overview of the available pharmacotherapy for the treatment of non-neurogenic overactive bladder in children36
Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges33
Pharmacotherapy developments in autophagy inhibitors for bladder cancer32
Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan30
Advances in the management of obstructive hypertrophic cardiomyopathy: The role of mavacamten29
Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy29
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis29
Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B28
A 2023 update on the advancements in the treatment of agitation in Alzheimer’s disease28
An overview of mineralocorticoid receptor antagonists as a treatment option for patients with heart failure: the current state-of-the-art and future outlook26
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases26
GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives24
Antidepressant medications in women aged 40 and older and the risk of fragility fractures: a systematic literature review and meta-analysis24
Promising therapies for adults with symptomatic obstructive hypertrophic cardiomyopathy: 2023 and beyond23
Current treatment options for Mycobacterium marinum cutaneous infections22
Bexagliflozin for type 2 diabetes: an overview of the data21
How useful is chemotherapy for atypical and anaplastic meningiomas?20
The pharmacological treatment and management of hyperhidrosis20
Momelotinib in myelofibrosis19
Pharmacotherapeutic options in pediatric obesity: an urgent call for further research19
An up-to-date overview of the pharmacotherapeutic options for premature ejaculation19
Zanubrutinib for the treatment of chronic lymphocytic leukemia19
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis19
0.14949107170105